The CCL2 ELISA data showed that plasma levels of CCL2 were significantly increased in the entire BC group compared to the total control group (benign breast tumor and healthy subjects) (p<0.001), similarly as the median levels of CA 15-3 (p<0.001). This evidence concerns the gene CCL2 and breast benign neoplasm.